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Approximately %90 of all renal malignancies are renal cell car-
cinoma (RCC). About 30% of all patients are diagnosed with meta-
static disease although improvements in diagnosis, especially
improved imaging techniques and the incidental diagnosis of many
tumors.1 Treatment of metastatic RCC is changed after approve-
ment of sorafenib in 2005, six more drugs were introduced.2 In ﬁrst
line therapy for patients with favorable or intermediate risk clear
cell RCC, sunitinib and pazopanib are approved. TKIs or m-TOR
inhibitors are the treatment options in the second-line. Recently,
improved overall survival beneﬁt has been shown of nivolumab, a
programmed death-1 (PD1) checkpoint inhibitor.3 In a recent study
response rate with medroxiprogesterone acetate was 9,7% (partial
response and stabile disease) compared with lapatinib.4 In earlier
studies with small numbers of patients response rate with
medroxiprogesterone was reported between 2% and 15%.5e7
We aimed to present a case report with metastatic renal cell
cancer who had durable response with medroxiprogesterone ace-
tate therapy after developed progression with multiple targeted
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59-year-old male was admitted to the urology clinic with right
ﬂank pain. Thorax-abdominal computed tomography (CT) detected
multiple suspicious nodules in the lung, and a renal mass favoring
malignancy in the right kidney. Patient underwent surgery of right
radical nephrectomy, and postoperative pathological examinations
revealed renal clear cell tumor with fuhrman grade 2 exceeding the
geroto fascia. Interferon-alpha was initiated subcutaneous 6 MU
three times a week dosing. After one year of therapy, interferon-
alpha was stopped since the patient achieved a stable disease
conﬁrmed by imaging methods. However, 3 years after the
completion of interferon-alpha therapy, a new right adrenal mass
3.5 cm in diameter, and multiple mediastinal lymphadenopathies
were determined in control abdomen and chest CT. Pathological
ﬁndings of the right adrenal metastasectomy material were
compatible with metastatic RCC. Sunitinib was commenced on 50
mgr daily with standard schedule of 4 weeks on and 2 weeks off.
Despite an initial positive clinical and radiological response to
sunitinib, patient had disease progression at the 18th month of
treatment. Therefore, evorolimus was initiated at 5 mgr twice daily
as the second line treatment of metastatic RCC. After an 18 months
of partial response, patient developed disease progression on
everolimus therapy. Patient was ultimately started on axitinib 5
mgr twice daily, with a good initial radiological response after 2
month of treatment. However, patient had disease progression at
the 5th month of axitinib therapy. Medroxiprogesterone acetate
160 mgr three times daily was commenced on as the 4th line
treatment in metastatic setting, with an ongoing favorable clinical
and radiological response at the 11th month of treatment. Patient is
still on medroxiprogesterone acetate treatment, with an ongoing
clinical and radiological response.3. Discussion
Patients with metastatic RCC generally have a poor prognosis.
Treatment of metastatic disease has dramatically changed with theting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
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m-TOR inhibitors, immunotherapy, and VEGF-based treatments. In
patients with advanced cancers, medroxiprogesterone acetate im-
proves quality of life by increasing appetite and energy.8,9 In met-
astatic renal cell cancer, medroxiprogesterone acetate have a
response rate of 2%e15%.4e7,10 Furthermore durable response longer
than 6e9monthswithmedroxiprogesterone is reported very rarely.
In the era of targeted therapies and immunotherapy in metastatic
RCC, it is highly important to note that we observed an ongoing
clinical and radiological response with 11 months treatment of
medroxiprogesterone acetate. Thus, despite the low response rates,
we would like to emphasize that medroxiprogesterone acetate
should be kept in mind not only as a palliative option but also as a
therapeutic agent in the metastatic setting of metastatic RCC.
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